Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus in Treating Patients With Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed intracranial glioblastoma multiforme~* Disease progression by MRI or CT scan~  * Confirmation of true progressive disease (not radiation necrosis) by positron-emission tomography, thallium scanning, MRI, or surgical documentation required if patient received prior interstitial brachytherapy or stereotactic radiosurgery~* Failed prior radiotherapy~* Phase I patients:~  * Eligible for salvage surgery~ * No limits on prior therapy~* Phase II patients:~  * Tumor progression by MRI or CT scan required within the past 14 days if recurrent disease is present~ * No prior therapy for more than 3 relapses~ * Recent resection of recurrent or progressive tumor allowed as long as all of the following conditions apply:~    * Recovered from surgery~   * MRI or CT scan performed no more than 96 hours since prior surgery OR within 4-6 weeks after surgery~   * Baseline MRI or CT scan performed within 14 days of study entry~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 60-100%~Life expectancy~* More than 8 weeks~Hematopoietic~* WBC at least 3,000/mm\^3~* Absolute neutrophil count at least 2,000/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 10 g/dL (transfusion allowed)~Hepatic~* Bilirubin less than 1.5 times upper limit of normal (ULN)~* SGOT less than 1.5 times ULN~Renal~* Creatinine less than 1.5 mg/dL~Other~* Cholesterol less than 350 mg/dL~* Triglycerides less than 400 mg/dL~* No concurrent disease that would obscure toxicity or dangerously alter drug metabolism~* No other significant uncontrolled serious medical illness that would preclude study participation~* No other cancer except non-melanoma skin cancer or carcinoma in situ of the cervix unless patient is in complete remission and off all therapy for that disease for at least 3 years~* No active infection~* No prior allergic reactions to compounds of similar chemical or biological composition to sirolimus~* No psychiatric illness that would preclude study participation~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* At least 1 week since prior interferon~Chemotherapy~* At least 2 weeks since prior vincristine~* At least 3 weeks since prior procarbazine~* At least 6 weeks since prior nitrosoureas~Endocrine therapy~* At least 1 week since prior tamoxifen~Radiotherapy~* See Disease Characteristics~* At least 4 weeks since prior radiotherapy~Surgery~* See Disease Characteristics~Other~* Recovered from prior therapy~* At least 1 week since prior noncytotoxic agents (except radiosensitizers)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Phase 1 (Type: EXPERIMENTAL): See intervention description.
- Phase 2 (Type: EXPERIMENTAL): See intervention description.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete